Phase I
Four companies, Pipeline Therapeutics, Prothena, Neuroplast, and Taysha Gene Therapies, announced launches of clinical trials in the CNS space.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
Biogen and Ionis Pharmaceuticals announced that their Phase I study of BIIB078 (IONIS-C9Rx) intended for ALS did not meet clinical endpoints, so they will discontinue the program.
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
Seattle-based Icosavax’s stock plunged 50% after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Small Pharma Inc. is developing a new approach to treat major depressive disorder (MDD) without using SSRIs or standard medications. Here’s what they are using.
The 4D pharma has shared positive interim results from its Phase I/II study of a combination therapeutic for the treatment of renal cell carcinoma (RCC).
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES